Mineralys Therapeutics (MLYS) Net Equity Issued and Repurchased (2022 - 2025)

Mineralys Therapeutics (MLYS) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $188.9 million in Q2 2025.

• For the quarter ending Q2 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $188.9 million; the trailing twelve-month figure through Mar 2026 stood at $188.9 million (changed N/A YoY), and the FY2025 full-year result was $188.9 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased grew to $188.9 million in Q2 2025, from -$203.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $203.6 million in Q1 2023 to a low of -$203.0 million in Q4 2023.
• A 3-year average of $51.1 million and a median of $58.8 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 271.71% in 2023, while the deepest fall reached 271.71% in 2023.
• Tracing MLYS's Net Equity Issued and Repurchased over 3 years: stood at $118.2 million in 2022, then tumbled by 271.71% to -$203.0 million in 2023, then soared by 193.05% to $188.9 million in 2025.
• Business Quant data shows MLYS's Net Equity Issued and Repurchased at $188.9 million in Q2 2025, -$203.0 million in Q4 2023, and -$581000.0 in Q2 2023.